Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Cognition Therapeutics的股票在公司提供了關於輕度至中度阿爾茨海默症的第2期SHINE研究生物標誌物分析更新後交易價格上漲。
Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Cognition Therapeutics的股價走高,此前該公司提供了針對輕度至中度阿爾茨海默氏病的SHINE二期研究的生物標誌物分析的最新情況。